找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Histiocytic Disorders; Oussama Abla,Gritta Janka Book 2018 Springer International Publishing AG 2018 langerhans cell Histiocytosis.hemopha

[復制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 16:36:30 | 只看該作者
Hematopoietic Cell Transplantation and Novel Therapies in Hemophagocytic Lymphohistiocytosis HLH, HCT is essential for preventing future episodes of fatal HLH in patients with genetic predisposition to HLH. Survival with HCT has increased significantly in recent years with the adoption of reduced intensity conditioning (RIC) regimens. However, RIC treatment protocols carry their own distin
42#
發(fā)表于 2025-3-28 22:25:48 | 只看該作者
43#
發(fā)表于 2025-3-29 02:09:38 | 只看該作者
Biology and Genomics of LCH and Related Disordersnslocations that produce fusion proteins which activate . occur more frequently in ECD than in LCH. The presence of some of these activating mutations in circulating cells or in CD34+ bone marrow cells suggests that these diseases may arise from transforming events in early myeloid precursors. ICH c
44#
發(fā)表于 2025-3-29 05:59:33 | 只看該作者
Central Nervous System Langerhans Cell Histiocytosisnation. Biopsies of such lesions are rare. In the few published cases biopsied, variable pathologies are described with perivascular inflammatory changes, variable neuronal loss, demyelination, and gliosis, but are nondiagnostic for CD1a+/CD207+ LCH cells. Granulomatous LCH can be responsive to chem
45#
發(fā)表于 2025-3-29 10:26:28 | 只看該作者
First-Line Treatment of Pediatric Langerhans Cell Histiocytosisactivation rates. The effect of further prolongation is being studied in the current LCH-IV protocol of the Histiocyte Society. It is to be expected that in the (near) future, the use of BRAF and MEK inhibitors may be introduced in first-line therapy, especially for very high-risk patients. For thes
46#
發(fā)表于 2025-3-29 11:43:44 | 只看該作者
47#
發(fā)表于 2025-3-29 16:01:58 | 只看該作者
48#
發(fā)表于 2025-3-29 21:34:41 | 只看該作者
49#
發(fā)表于 2025-3-30 01:58:56 | 只看該作者
50#
發(fā)表于 2025-3-30 04:02:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 16:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
丘北县| 天全县| 临沭县| 墨竹工卡县| 芜湖市| 禹州市| 平陆县| 理塘县| 富平县| 柘城县| 丰顺县| 西华县| 巴彦县| 汤原县| 姜堰市| 荣成市| 长垣县| 依安县| 治多县| 湾仔区| 神木县| 白玉县| 苗栗市| 南丹县| 黑山县| 砚山县| 东乡县| 平泉县| 六盘水市| 南漳县| 巴彦淖尔市| 鹿泉市| 延川县| 怀来县| 那坡县| 普兰县| 丰台区| 包头市| 福建省| 婺源县| 蓬莱市|